ClinicalTrials.gg
RecruitingNCT04313270Updated Mar 8, 2021

Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab®

An observational study in Hypercholesterolemia, Familial, sponsored by Federico II University. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-08.

Sponsored by Federico II University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2022, 3 years 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2017; still recruiting 8 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
25
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Hyperlipoproteinemia Type II with a site in Italy — 4 open to participants now, 4 under way, 2 of them phase 3. Hyperlipoproteinemia Type II · Italy.

Started
2017
with 1 other
Observational
4 of 19
2 open now
Registered
14th of 19
by date
Lead sponsor
1 of 19
Federico II University

Among the 19 studies in Hyperlipoproteinemia Type II with a site in Italy, this one is one of 2 that started in 2017, is one of 4 observational ones, and was the 14th registered.

Hyperlipoproteinemia Type II

251 studies on the registry are indexed under Hyperlipoproteinemia Type II; 57 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

4 of the 19 studies in Hyperlipoproteinemia Type II with a site in Italy are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 37 Hyperlipoproteinemia Type II studies recruiting now, 17 (46%) set no upper age limit and 16 (43%) stop at 75 or younger; 17 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Hyperlipoproteinemia Type II with a site in Italy, or all of them as a file.
02

Study summary

Protein convertase subtilisin kexin type 9 (PCSK-9) inhibitors demonstrated efficacy in cholesterol reduction and in the prevention of cardiovascular events. The investigators will evaluate changes in lipid profile, oxidation markers and subclinical atherosclerosis in patients with familial hypercholesterolemia (FH) during 12 weeks of treatment with a PCSK-9 inhibitor, Evolocumab®.

Read the detailed description

Several studies emphasize the role of high levels of low-density lipoprotein cholesterol (LDL-C) as the main causative factor in atherosclerosis development. Among patients with hypercholesterolemia, those with very high levels of LDL-C exhibit increased prevalence of subclinical atherosclerosis and a higher atherosclerosis progression, thus leading to a significantly higher CV risk. Endothelial dysfunction is the earliest stage of the atherosclerotic process and even a trigger of CV events. Flow-mediated dilation (FMD) is widely accepted as an accurate and non-invasive method to assess vascular reactivity and, in turn, as a surrogate marker of subclinical atherosclerosis and an independent predictor of CV events. It's well known that hypercholesterolemia has been associated with decreased endothelial function and increased oxidative stress. Although statin treatment represented for years the gold standard as lipid lowering therapy, the target LDL-C is not always achieved, mainly among patients with very high levels of LDL-C. More recently, PCSK-9 inhibitors demonstrated efficacy in LDL-C reduction, in the prevention from CV events and in atherosclerotic burden regression. Some data showed an effect of PCSK-9 inhibitors on endothelial function, but no evidence is available on effect on LDL subfractions. Small dense LDL (sd-LDL) are considered an emerging risk factor for cardiovascular disease due to a greater atherogenic potential [ ] and are important markers for predicting CV risk.

03

Conditions studied

  • Hypercholesterolemia, Familial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

consecutive patients attending the lipid clinic of the Department of Clinical Medicine and Surgery, Federico II University Hospital with very high levels of LDL-C (above the 95th percentile when compared with a sex- and age-matched general population), normal triglyceride levels and presumed autosomal dominant transmission of hypercholesterolemia in the family were screened for inclusion in the present study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of FH (clinical and/or genetic)
  • eligibility of patients to start a treatment with PCSK-9 according to 2016 ESC guidelines.

Exclusion criteria

Exclusion Criteria:

  • age \< 18 years
  • inability to understand or sign the
  • high level of transaminases ( >3x upper normal limit)
  • hypertriglyceridemia ( >150 mg/dl)
  • end-stage renal disease (filtration rate \< 30 ml/min/mq)
  • current malignant disease or a diagnosis of in the 2 years prior to the first visit
  • previous exposure to PCSK-9 inhibitors
  • presence of hypercholesterolemia secondary to other causes (hypothyroidism, hormone therapies, etc.)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
25 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with FH starting a treatment with Evolocumab®

    Drug: Evolocumab

Interventions

  • 12 weeks of treatment with Evolocumab

06

What researchers measure

Primary outcomes

  1. Subclinical atherosclerosis

    evaluation of subclinical atherosclerosis in patients receiving Evolocumab

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Matteo Di Minno
    Napoli, 80131, Italy
    Recruiting
08

References and documents

Publications

  • Iannuzzo G, Buonaiuto A, Calcaterra I, Gentile M, Forte F, Tripaldella M, Di Taranto MD, Giacobbe C, Fortunato G, Rubba PO, Di Minno MND. Association between causative mutations and response to PCSK9 inhibitor therapy in subjects with familial hypercholesterolemia: A single center real-world study. Nutr Metab Cardiovasc Dis. 2022 Mar;32(3):684-691. doi: 10.1016/j.numecd.2021.10.025. Epub 2021 Nov 11. PubMed 34991937 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2017 (actual). Primary completion is estimated for Dec 2022, 60 months after the start.

Of 32 observational studies under Hyperlipoproteinemia Type II, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 82. This study's planned 60 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2020
First posted
Mar 18, 2020
StartActual
Dec 1, 2017
Primary completionEst.
Dec 1, 2022
CompletionEst.
Dec 1, 2025
Last update
Mar 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04313270
Responsible party
Matteo Di Minno (Associate Professor of Internal Medicine, Federico II University) — Principal investigator
First posted
Mar 18, 2020
Start date
Dec 1, 2017
Primary completion
Dec 1, 2022 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Mar 8, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion